University of Illinois

H. Lee Moffitt Cancer Center and Research Institute, Inc.

The Children's Hospital of Philadelphia

Joel Bergman

Alan P Kozikowski

Alejandro V Villagra

Eduardo M Sotomayor

Karrune Veeraprasert Woan

Jay Hans Kalin

Kyle Vincent Butler

Wayne W Hancock

Irina Gaisina

Sida Shen

Irina N Gaisina

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Selective histone deactylase 6 inhibitors

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

HDAC inhibitors and therapeutic methods using the same

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed. 

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Growing community of inventors

Chicago, IL, United States of America

Joel Bergman